Oncology
George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research, and as such demonstrating product value in terms of clinical effectiveness, specialized cohorts and tolerability.
George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research, and as such demonstrating product value in terms of clinical effectiveness, specialized cohorts and tolerability.
George Clinical is a leading provider of oncology trial, scientific, and operational solutions throughout the Asia-Pacific, USA and Europe.
As a leader in the design and delivery of care-based, oncology research, George Clinical has access to significant global investigator networks, experienced project teams, oncology experts, and scientific leaders to design and deliver oncology trials, with the latest immunotherapies, to the highest scientific standards. By accessing some of the world’s most experienced medical, scientific and operational teams in oncology research, George Clinical is uniquely placed to meet the increasingly complex and specialized demands of modern oncology research and thus demonstrates product value in terms of clinical effectiveness, specialized cohorts, and tolerability.
Exceptional medical, scientific and operational expertise makes George Clinical an ideal partner for clinical trials throughout North America, Europe and the Asia-Pacific.
Oncology Expertise
George Clinical has extensive experience in all phases of oncology programs including, MTD, early Phase I, II and III and late-phase trials, health economics and outcomes research. Our full services team is comprised of scientific leaders, doctors, nurses, biostatisticians and trial management professionals that work together to ensure timely delivery of quality trial data on time and on budget.
George Clinical offers a unique combination of scientific leadership and operational capabilities to design and deliver studies for sponsors, no matter the complexity. George Clinical offers:
George Clinical’s extensive experience in oncology trials provides sponsors with the confidence that their oncology trial will be delivered on time, on budget and to the highest scientific standards.
Our clinical trial services in oncology clinical trials include:
Susan is responsible for U.S. project and clinical operations, including project management, study startup, monitoring and site management services. With over 25 years in clinical research, she brings experience in all phases of clinical trials, multiple therapeutic areas including over 12 years in oncology, and key leadership roles in clinical operations and financial management. She has helped develop or improve services for multiple U.S. Contract Research and Site Management organizations, as well as a national oncology site network. Her work with global and cross-functional teams brings added value to the George Clinical team as the Global Head of Therapeutic Strategy, Oncology.
Dr. Khasraw’s research focuses on the development and design of innovative clinical trials to improve patient outcomes of primary and metastatic cancers of the central nervous systems. He is a neuro-oncologist, professor of medicine and Deputy Director of the Center for Cancer Immunotherapy at Duke where he is tasked with speeding up translation for scientists across all departments and tumor sites. Dr. Khasraw is leading several clinical and translational programs moving from bench to bedside and back to the bench―including leadership of several multicenter early phase immunotherapy clinical trials and collaborations in and outside Duke and across disciplines.
Professor Thomas’ research focus is on the application of genomic technologies to the understanding and management of cancer. He is the inaugural Director, Centre for Molecular Oncology, University of New South Wales; Head of the Genomic Cancer Medicine Laboratory, Garvan Institute of Medical Research; and CEO of Omico. He founded the Australasian Sarcoma Study Group and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre. Professor Thomas leads the International Sarcoma Kindred Study and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval.
Dr. Wabnitz has extensive experience in clinical development with a unique combination of clinical medicine, pharmacology, toxicology and industry drug development experience. He is Consultant Physician at Royal Adelaide Hospital (FRACP), Australia. He has acted as an investigator and Medical Monitor in over 50 first in human Phase I/II clinical trials as well as previously being the Executive Medical Director of a leading Australian Phase I clinical unit. He is qualified in regulatory submissions, HREC reviews/approvals, clinical trial design and execution, medical monitoring and extensive clinical trial networks within Australia, Asia, EU and the USA.
Dr. Schwartzberg’s research interests focus on breast cancer, supportive care, precision medicine and patient reported outcomes. He is Chief, Medical Oncology and Hematology at the at the William N. Pennington Cancer Institute at Renown Health and Professor of Clinical Medicine, University of Nevada School of Medicine Reno. He has published over 300 peer reviewed manuscripts, book chapters and monographs. He is founding editor in chief of the Elsevier website Practice Update Oncology and founding editor in chief of the journal Community Oncology. Dr. Schwartzberg was honored as the 2023 Legends in Cancer honoree at the Best of Breast conference for his contributions to the field of breast cancer.
Dr. Boccia focuses on cutting-edge drug development. He is Medical Director of the Center for Cancer and Blood Disorders in Bethesda, Maryland, where he has up to 60 clinical trials at all times, and 10 FTEs for research. He is also Clinical Associate Professor of Medicine at Georgetown University in Washington, DC. and serves as the Chief Medical Officer for the International Oncology Network (ION). He is a member of numerous professional societies including ASCO, ASH and the American College of Physicians.
Dr Jeremy Teoh’s research interests are in bladder and prostate cancer including urinary biomarkers for bladder cancer and androgen deprivation therapy for prostate cancer. He is Assistant Dean (External Affairs) and Assistant Professor of the Faculty of medicine, The Chinese University of Hong Kong. He is also Chairperson of the Younger Fellows Chapter of the College of Surgeons of Hong Kong and Vice-Chair of the Young Fellows Chapter of the Hong Kong Academy of Medicine, and has been the Director of the Lions Kidney Educational Centre & Research Foundation since 2016.
Dr. Teoh developed a global consensus statement to standardize the en bloc resection approach and is studying the urinary biomarkers, tumour heterogeneity and molecular classification of bladder cancer. He has received numerous research grants with a total funding of more than HKD 30 million and has been serving as a member for several advisory boards for prostate cancer and bladder cancer. Dr. Teoh is the founder of the UroSoMe (Urology Social Media) working group and believes that social media plays an important role in the modern era of medicine.
Dr. VanderWalde specializes in melanoma and is experienced in genomic tumor assessment, public health, tumor immunotherapy, medical ethics and precision oncology. He is the Global Head of Clinical Research at Caris Life Sciences and works as Research Faculty at West Cancer Center where he served as the Director of Research from 2014 to 2021. He is also Professor in the Division of Epidemiology at the University of Memphis School of Public Health. Dr. VanderWalde has extensive experience in clinical research, including the design and conduct of clinical trials, results reporting, regulatory filing and interactions between investigators and the pharmaceutical industry.
Dr. Loong’s research focuses on sarcoma medical oncology, neuro-oncology, thoracic oncology and experimental therapeutics (Phase I trials). Based in Hong Kong, he holds conjoint appointments of Clinical Associate Professor, Department of Clinical Oncology and Deputy Medical Director, Phase 1 Clinical Trials Centre, The Chinese University of Hong Kong. He is also the current and founding convenor of the Prince of Wales Hospital Adult Sarcoma Multidisciplinary Team. He has conducted over 50 oncology trials as either a Principal Investigator or Co-Investigator. Dr. Loong is a founding executive committee member of the Asia Pacific Oncology Drug Development Consortium.
Dr. Pluard’s research focuses on novel therapies in metastatic breast cancer. He is Medical Director at Luke’s Cancer Institute and Founding Director of Saint Luke’s Koontz Center for Advanced Breast Cancer, Kansas City. Previously, he was Associate Professor of Medicine and Clinical Director of Breast Oncology at Washington University Siteman Cancer Center, St. Louis. His clinical focus is exclusively metastatic breast cancer care including advanced genomic and immunotherapy treatments, and he is a major contributor to numerous clinical trials. Saint Luke’s Cancer Institute has the region’s largest portfolio of Stage 4 breast cancer clinical trials―through partnerships, access to >200 trials.
Dr. Chandler focuses on blood cancers with a specific focus of cellular therapy in multiple myeloma and lymphoma. He heads up malignant hematology research at West Cancer Center in Memphis, TN. He spent five years as a member of the NCCN guidelines committee for multiple myeloma and is involved in multiple clinical trials ranging from Phase I to III in malignant hematology. Dr. Chandler has been involved with building a stem cell transplant/CAR-T program and is currently doing so again with a focus on out-patient administration.
